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a b s t r a c t 
Background: All-cause excess mortality is a comprehensive measure of the combined direct and indirect 
effects of COVID-19 on mortality. Estimates are usually derived from Civil Registration and Vital Statistics 
(CRVS) systems, but these do not include non-registered deaths, which may be affected by changes in 
vital registration coverage over time. 
Methods: Our analytical framework and empirical strategy account for registered mortality and under- 
registration. This provides a better estimate of the actual mortality impact of the first wave of the COVID- 
19 pandemic in Peru. We use population and crude mortality rate projections from Peru’s National Insti- 
tute of Statistics and Information (INEI, in Spanish), individual-level registered COVID-19 deaths from the 
Ministry of Health (MoH), and individual-level registered deaths by region and age since 2017 from the 
National Electronic Deaths Register (SINADEF, in Spanish). 
We develop a novel framework combining different estimates and using quasi-Poisson models to esti- 
mate total excess mortality across regions and age groups. Also, we use logistic mixed-effects models to 
estimate the coverage of the new SINADEF system. 
Findings: We estimate that registered mortality underestimates national mortality by 37 • 1% (95% CI 23% 
- 48 • 5%) across 26 regions and nine age groups. We estimate total all-cause excess mortality during the 
period of analysis at 173,099 (95% CI 153,669 - 187,488) of which 108,943 (95% CI 96,507 - 118,261) were 
captured by the vital registration system. Deaths at age 60 and over accounted for 74 • 1% (95% CI 73 • 9% 
- 74 • 7%) of total excess deaths, and there were fewer deaths than expected in younger age groups. Lima 
region, on the Pacific coast and including the national capital, accounts for the highest share of excess 
deaths, 87,781 (95% CI 82,294 - 92,504), while in the opposite side regions of Apurimac and Huancavelica 
account for less than 300 excess deaths. 
Interpretation: Estimating excess mortality in low- and middle-income countries (LMICs) such as Peru 
must take under-registration of mortality into account. Combining demographic trends with data from 
administrative registries reduces uncertainty and measurement errors. In countries like Peru, this is likely 
to produce significantly higher estimates of excess mortality than studies that do not take these effects 
into account. 
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Research in context 
Evidence before this study 
We searched PubMed, Google Scholar, medRxiv, and So- 
cArXiv for studies published up to May 27, 2020, using the 
keywords “excess mortality” and “under-registration” or “sub 
registration,” combined with “coronavirus” or “SARS-CoV-2”
or “COVID-19.” We found studies estimating cumulative mor- 
tality in high-income countries in Europe and North Amer- 
ica solely based on official death counts. We found stud- 
ies computing overall COVID-19 mortality for a small num- 
ber of LMICs. Prior research shows a significant percentage of 
under-registration of deaths in LMICs. 
Added-value of this study 
To our knowledge, we provide the first estimate of excess 
mortality associated with COVID-19 that accounts for both 
registered and unregistered deaths in a LMIC. We develop 
an analytical strategy to address common challenges faced 
by LMICs, such as low completion rates of death certificates, 
missing data, and inconsistency and variability of data across 
regions and age groups. We show our method is robust for 
small samples, including for subnational regions and specific 
age groups. 
Implications of all the available evidence 
Our approach shows the importance of accounting for un- 
registered deaths based on demographic trends to generate 
robust estimates of excess mortality associated with COVID- 
19. It suggests that previous reports of COVID-19 related mor- 
tality in Peru were substantial underestimates. 
. Introduction 
Monitoring mortality is an essential part of the public health 
esponse to the COVID-19 pandemic. In many countries, COVID-19 
ortality monitoring has been hindered by failures to capture all 
eaths or to accurately attribute the cause of death [1] . Disentan- 
ling the contribution of COVID-19 to overall mortality is especially 
hallenging, as many people who die from COVID-19 also have 
ther conditions, such as cardiovascular disease and diabetes [2] . 
ome countries apply different cut-off times between a positive 
OVID-19 test and death when attributing mortality to this cause 
3] . Also, the pandemic has led to large numbers of deaths not di- 
ectly attributable to COVID-19 (either exclusively or in part), due 
o effects such as reduced access to treatment for other conditions 
 4 , 5 ]. Conversely, there is evidence that lockdowns have sometimes 
educed expected rates of mortality from causes such as road traf- 
c injuries and homicides [6] . 
In the absence of good data on these different effects, robust 
stimation of all-cause excess mortality offers the most complete 
nd reliable approach for gauging the overall impact of the pan- 
emic on a defined population over a fixed period [7] . Excess mor- 
ality refers to the number of additional deaths occurring over a 
ime period when specific conditions apply (in this case, the pres- 
nce of COVID-19), compared to the number of deaths we might 
easonably expect over the same period based on historical data. It 
aptures deaths directly attributed to COVID-19 and those resulting 
rom other consequences of the pandemic, to provide an estimate 
f the overall mortality effect [8] . 
Excess mortality estimates based on registered deaths have 
een computed for high-income countries by surveillance agencies 
 9 , 10 ], academia [11–14] and the media [15–18] . However, these2 ata are often incomplete or inaccurate, especially in many low 
nd middle-income countries (LMICs). The Global Burden Disease 
GBD) estimates only 64% of global deaths were registered in 2015 
19] . In most LMICs, responsibility for mortality data is divided be- 
ween different national and subnational agencies [20] . This can 
ause extended delays in national reporting and discrepancies be- 
ween different sources [ 12 , 21 ]. Disaggregation of summary data 
y different geographical areas or demographic groups is usually 
ery limited [22] . These shortcomings explain the lack of published 
tudies of excess mortality in LMICs [ 23 , 24 ]. 
We deploy an array of analytical tools to address these issues 
nd we apply them to the case of Peru during the first wave of 
he pandemic. Peru is a geographically diverse country with three 
atural regions: a narrow dry coast in the west, the Andean region, 
nd a large, sparsely populated rainforest region to the east. Peru 
s divided into 26 administrative regions ( Figure 1 ). Peru’s National 
nstitute of Statistics and Information (INEI) estimated the national 
opulation was around 32.8 million in 2020, with a growth rate 
f around 1% year. The population aged 65 and over has increased 
apidly over the last two decades, with yearly growth rates of over 
.5%. By contrast, the growth rate of younger age groups has been 
alling, with an absolute decline in the population aged under 20 
rom year 2010 onwards [35] . 
Between 18 March and December 31, 2020, Peru reported 
6,036 deaths directly caused by COVID-19. This official figure only 
ncludes cases with positive COVID-19 test results, but rates of test- 
ng have been low compared to other Latin American countries 
25,26] . Also, many tests have used low sensitivity devices, poten- 
ially generating false negatives [27] . A separate study undertaken 
n association with the government applies a wider set of criteria 
o identify COVID-19 deaths [30] . Controversially, it categorises any 
eath in households where at least one person tested positive for 
OVID-19 as a “potential COVID-19 death”, even if the deceased 
as not tested. This generates an estimate of 89,844 potential 
OVID-19 deaths from March 1 st to November 30 th , 2020: equiv- 
lent to one of the highest per capita death rates in the world. 
The large differences between these two estimates, which cover 
imilar periods of time, reflect the level of uncertainty about 
OVID-19 mortality in Peru. Estimates of all-cause excess deaths 
ay offer a more reliable indicator of the pandemic’s impact, but 
aps in death registration impede robust comparisons over time. 
lso, Studies from other LMICs show registration coverage often 
aries significantly between sub-regions and age groups, hinder- 
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Figure 2. Crude death rates during 2017–2020 by Region - Peru. Grey lines indicate deaths during years 2017 to 2019 and red lines during 2020. Vertical dashed lines 




























































ng comparisons at these levels [ 32 , 33 ]. In 2017, Peru adopted a
ew online register, placing anonymised individual-level data on 
ortality and COVID-19 in the public domain [34] . Coverage of the 
ew system has increased over time, but it remains lower than for 
he paper-based one [35] . Also, registration rates are not reported 
t the subnational level, hindering analysis of geographical and age 
atterns. Consequently, comparisons over time must take increased 
egistration into account. 
To resolve these challenges, we develop an analytical frame- 
ork and empirical strategy, which deal with both registered and 
nregistered mortality, changes in registration coverage over time 
nd variations in coverage between regions and age groups. This 
dds value to the methods applied by other studies of excess mor- 
ality, which focus exclusively on registered deaths [31–33] . We 
est the feasibility of this method by applying it to Peru during 
020 and consider its potential suitability for LMICs with similar 
aps and inconsistencies in mortality registration. 
. Methods 
.1. Data 
We use data from two Ministry of Health (MoH) mortality reg- 
stration systems. Anonymised individual-level registered deaths 
rom the National Electronic Deaths Register (SINADEF, in Span- 
sh) from 2017 to 2020 are divided into 26 regions and nine 
ge groups [36] . In 2017 Peru began to shift from a paper-based 
ystem to an electronic one, which led to a growth in coverage 
from 98,552 reported deaths in 2017 to 114,449 in 2019). SINADEF 
ought to strengthen the mortality information system by improv- 
ng the coverage and quality, and standardising registration pro- 
esses. Data inclusion in the public database is delayed by pro- 
essing and checking procedures, such as the inclusion of manual 
eaths certificates, quality control and the correction of errors in 3 eaths certificates [34] . Coverage of SINADEF was estimated to be 
4.0% of total deaths in 2018 [35] . However, coverage varies among 
egions, impeding comparisons of spatial and temporal trends. Ad- 
itionally, we use anonymised individual-level registered deaths by 
egion and age group from MoH COVID-19 tracking systems [63] . 
oth sets of data include date of death, age, sex, date of birth and 
dministrative region, and were collected on May 30, 2021. The 
INADEF data set consists of 573,054 observations, with an average 
ge of 66 • 35 (s.d. 23 • 46). MoH COVID-19 data set consists of 36,036
eaths, with an average age of 65 • 96 (s.d. 14 • 66). A higher propor-
ion of males deaths matches similar patterns in other countries 
ue to immunological differences [13-14] . We also use INEI pop- 
lation and mortality projections for recent years, by region and 
ge group. These projections are based on decennial censuses (the 
ost recent in 2017) and annual health and population surveys 
35] . 
Figure 2 shows weekly registered crude death rates by region 
or 2017 to 2020. There are clear differences between regions: Mo- 
uegua (coast) and Arequipa (Andes) show the highest rates, while 
mazonas (in Amazonia) and Ayacucho (Andes) show the lowest. 
ll regions other than Apurimac, saw an initial peak at some point 
etween week 20 and week 40. All regions then saw significant 
eclines, although a second peak occurred in Lima and Pasco in 
eeks 50 to 52. We also observe that weekly mortality growth var- 
ed across time. We restrict our excess mortality analysis to those 
eeks where a significant change can be detected for each region, 
sing 0 • 60% as a threshold criterion of weekly change [37] (vertical 
ines in Figure 2 ). 
.2. Excess mortality methods 
Figure 3 presents our approach to estimate excess mortality. 
his can be decomposed into three terms: (i) excess SINADEF reg- 
stered deaths; (ii) unregistered excess deaths; and (iii) unregis- 
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Figure 3. Conceptual representation of empirical strategy Grey lines indicate deaths during years 2017 to 2019 and red lines during 2020. Vertical dashed lines indicate the 




















































ered COVID-19 deaths. Figure 4 summarises our empirical strategy 
ased on data sources used (squares), statistical analysis performed 
diamonds) and outputs (circles). 
To estimate the first term, excess SINADEF registered deaths - 
̂ xces s Reg -, we first fit quasi-Poisson regressions to address the 
ver-dispersed nature of the data to weekly deaths, Deaths , as fol- 
ows: 
log ( Deaths ) = β0 + β1 COVID − 19 + Fourier series + β2 ∈ t−1 
+ 
∑ 
βk φk ( Week ) + log ( Pop ) + ∈ t (1) 
here we fit a natural cubic B-spline function φk ( Week ) on weeks 
nd Fourier series (with yearly periods and 6 pairs of sines and 
osines) to address long-term trends and seasonality [38] . Addi- 
ionally, we use lagged residuals ∈ t −1 [39] and the log of the pop- 
lation in 2020, log ( Pop ) as an offset. Finally, we compute a di- 
hotomous variable COVID − 19 starting in the week corresponding 
o the pandemic onset for each region ( Figure 2 ). We calculate the
elative risk RR of those β1 under a statistical significance thresh- 
ld (p < .05) to compute registered excess mortality as a population 
ttributable fraction (PAF) [40] , as follows: 
̂ Exces s Reg = ( RR − 1 ) / RR ∗ n (2) 
here n is the weekly number of deaths and represents a frac- 
ion of the total mortality of the period where COVID − 19 = 1 in 
quation (1) . 
The second term, unregistered excess deaths - ̂ Exces s Not reg - 
 estimates mortality delayed or absent in official registers and 
s computed as a fraction of ̂ Exces s Reg . We start by predicting 
INADEF completeness ̂ Reg complete by modelling random-effects 
ogistic regressions [41] for each region j using for 2017 and 2019, 
epresented by Year . We exploit variability in INEI mortality rates, 
opulation aged 60 years and over and rurality to address potential 
ifferences in terms of registration completeness, using the equa- 4 ion: 
ogit 
(
Reg complet e j 
)
= β0 + β1 ∗ RegCDR + β2 ∗ RegCD R 2 
+ β3 ∗ complete < 5 + β4 ∗ P 60+ 
+ β5 ∗ log ( 5q0 ) + β6 ∗ LPG 
+ β7 ∗ Year + ∈ + γ j (3) 
here RegCDR and RegCD R 2 are the Crude Death Rates, 
omplete < 5 indicates registration coverage of child mortality - 
s a relevant proxy measure of overall mortality registration in a 
opulation-, log( 5q0 ) is the logarithm of under-five mortality rate 
nd P 60+ represents the fraction of the population at 60 years and 
ver based on INEI projections. LPG is the share of households 
hat use liquefied petroleum gas for cooking. This is an accept- 
ble proxy for rurality in Peru, as 81 • 8% of rural households pri- 
arily use solid fuel compared to 9 • 8% of urban ones, which typ- 
cally cook with liquefied petroleum gas [42] . Rurality is an im- 
ortant factor to explain delay and under-registration of deaths as 
he system requires access to internet and computers. Addition- 
lly, ∈ is the error term and γ j is the region-level random effect. 
eg complet e j is computed using the inverse logit of the predicted 
alues, which provides a regionally adjusted SINADEF complete- 
ess estimate. We use regional completeness estimates for the year 
019 in all cases but Lambayeque, where we average both to reflect 
he significant differences between them. 
Finally, unregistered excess deaths are based on ̂ Exces s Reg from 
quation (2) and ̂ Reg complete from equation (3) , as follows: 
̂ Exces s Not reg = 
∑ 
̂ Exces s Reg ∗
(
1 




The last term, unregistered COVID-19 deaths, 
ˆ Death s COVID −19 not reg , is computed to correct for situations where the 
roportion of cumulative cases of reported COVID-19 deaths for 
hat period exceeds SINADEF values. This occurs mostly in younger 
ge groups. The calculation is conditional on registered excess 
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eaths being lower than officially registered COVID-19 deaths for 
ach region and specific age group as follows: 
ˆ Death s COVID −19 not reg 
= 
{
ˆ μDeath s COVID −19 Reg − ˆ μExces s Reg if ˆ μDeath s COVID −19 Reg > ˆ μExces s Reg , 
0 if ˆ μDeath s COVID −19 Reg < ˆ μExces s Reg . 
(5) 
Finally, we estimate total excess deaths for different scenarios. 
A first scenario is when there is no solid evidence suggesting 
nder-registration of deaths for some regions or age groups and, 
herefore, no scope to expand registration over time. This usually 
ccurs in areas and age groups with very small populations. In 
hose cases, ̂ Exces s Not reg is set to 0 to avoid adding negative values 5 o the sum. A second scenario relates to younger age groups who 
n some regions have not been significantly affected by COVID-19 
ortality. This case occurs when β1 in equation (1) is not statis- 
ically significant and therefore we set ̂ Exces s Reg = 0 . A third sce- 
ario is when some groups have fewer deaths than expected, due 
o effects such as reduced road traffic injuries. In these groups 
̂ xces s Reg ≤ 0 and ̂ Exces s Not reg = 0 are included in the final esti- 
ate. A fourth scenario is when models underestimate the official 
umber of deaths such as COVID Reg > ̂ Exces s Reg . In this case, we 
se the former as registered deaths. Equation (6) summarises the 
stimate of ̂ Excess T min / mean / max as follows: 
̂ Excess T min / mean / max = ̂ Exces s Reg min / mean / max + ̂ Exces s Not reg 
+ Death s COVID −19 Not Reg (6) 
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Figure 5. Comparison of completeness methods. Each dot indicates Regions, the blue line depicts the estimation of the logit regression, and the vertical dashed line the full 





































Finally, we estimate total mortality during 2020 by adding 
̂ xcess T min / mean / max from equation (6) and SINADEF expected 
eaths for 2020, ̂ SINADE F Not excess , adjusted by 
̂ Reg complete from 
quation (3) , as follows: 
̂ ota l Mortality | 2020 = ̂ Excess T min / mean / max 
+ 
( 
̂ SINADE F Not excess ∗
( 
1 
̂ Reg complet e j 
) ) 
(7) 
To address the relative level of mortality in 2020, we compute 
ll-cause age-standardised death rates per 1,0 0 0 people derived 
rom the estimated total excess deaths. We apply direct standard- 
zation methods [43] using INEI population estimates by region 
nd age group for 2020 as the standard population [44] . 
As a robustness check for excess mortality estimates, we esti- 
ate a mortality baseline for each age group fitting either a Gen- 
ralised Linear Model with Poisson or Negative binomial distri- 
utions, depending on the data’s over-dispersion. The model in- 
ludes natural splines and sinusoidal components to account for 
ecular changes and seasonality in mortality, as well as interpo- 
ated weekly exposures to control for changes in age structure over 
ime. 95% prediction intervals were estimated using 2,0 0 0 boot- 
trapping iterations. Excess mortality is computed as the differ- 
nce between observed mortality and the baseline, only including 6 eeks in which observed mortality was above the upper predic- 
ion interval. 
Role of the funding source: There was no funding for this 
tudy. 
. Results 
Estimates of completeness of SINADEF registration derived from 
ur logistic regression model fit the data according to marginal and 
onditional r 2 and Root Mean Square of Errors parameters. Model 
t and goodness-of-fit are presented in Appendix 1. 
As a data validity test, we compare our estimations with the 
vailable data in the CRVS system for 2017 and 2019 ( Figure 5 ).
e find strong correlations between both estimations across years 
r(25) = .81 and .87, p < .01, two-tailed). CRVS based estimation 
hows several values (to the right of vertical lines) where SINADEF 
egistration is larger than CRVS, especially when completeness is in 
he higher end. For 2019, while the CRVS system estimates 159,706 
eaths, we predict 189,991, which is similar to INEI estimations 
188,043). This is consistent with current estimations of CRVS com- 
leteness gaps [45] . 
Logistic regression based on SINADEF shows an outlier value 
or Lambayeque (bottom of right panel), which is reflects a consis- 
ent lack of registration during 2019. We address those anomalies 
hoosing the highest registration completeness proportion for each 
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Figure 6. Estimation SINADEF completeness of death registration before pandemics 
- Peru. 
Table 1 
Summary of estimations, Peru, 2020. 
Terms Estimates (95% CI) 
COVID-19 deaths (MoH) 1,222 
Registered excess deaths 108,943 (96,507 – 118,261) 
SINADEF completeness registration 62 • 9% (51% - 77%) 
Total excess mortality 173,099 (153,669 – 187,488) 























Estimated total excess deaths by region 
Region Total excess Registered excess 
AMAZONAS 87,781 (82,294 – 92,504) 50,925 (47,738 – 53,666) 
ANCASH 15,661 (14,575 – 16,465) 7,733 (7,196 – 8,131) 
APURIMAC 8,091 (7,152 – 8,819) 6,502 (5,742 – 7,082) 
AREQUIPA 7,144 (6,536 – 7,610) 6,215 (5,680 – 6,617) 
AYACUCHO 5,962 (5,252 – 6,386) 2,784 (2,475 – 2,984) 
CAJAMARCA 5,616 (4,873 – 6,207) 5,273 (4,564 – 5,829) 
CALLAO 5,345 (4,012 – 6,291) 1,806 (1,369 – 2,129) 
CUSCO 4,964 (4,782 – 5,074) 4,437 (4,268 – 4,531) 
HUANCAVELICAICA 4,252 (3,691 – 4,678) 4,226 (3,659 – 4,645) 
HUANUCO 4,155 (3,408 – 4,756) 3,490 (2,851 – 3,999) 
4,071 (3,289 – 4,661) 2,526 (2,037 – 2,891) 
JUNINSAN MARTIN 3,534 (2,775 – 4,081) 1,870 (1,447 – 2,162) 
LA LIBERTAD 3,096 (2,255 – 3,759) 2,526 (1,823 – 3,067) 
LAMBAYEQUE 2,841 (2,307 – 3,166) 1,645 (1,152 – 1,932) 
LIMA 2,272 (1,566 – 2,823) 1,811 (1,237 – 2,253) 
LORETO 1,623 (639 – 2,236) 960 (440 - 1330) 
MADRE DE DIOS 1,160 (893 – 1,326) 984 (753 – 1,120) 
MOQUEGUA 1,087 (884 – 1,205) 889 (718 - 982) 
PASCO 958 (715 – 1,112) 755 (558 - 873) 
PIURA 891 (464 – 1,145) 353 (181 - 482) 
PUNO 873 (424 – 1,016) 264 (170 - 314) 
658 (174 - 894) 261 (68 - 363) 
TACNA 500 (319 - 607) 492 (284 - 591) 
TUMBES 307 (209 - 376) 154 (77 - 207) 
UCAYALI 260 (182 - 292) 62 (18 - 81) 
Table 3 
Estimated total excess deaths by age group 
Age range Total excess Registered excess 
< 10 209 (141 - 259) -53 (-262 - 64) 
10-19 221 (134 - 272) 91 (20 - 131) 
20-29 1,407 (774 – 1,826) 732 (354 - 980) 
30-39 4,261 (2,899 – 5,138) 2,592 (1,698 – 3,151) 
40-49 12,697 (11,168 – 13,739) 8,009 (6,995 – 8,693) 
50-59 26,114 (23,687 – 27,763) 16,440 (14,939 – 17,493) 
60-69 42,528 (39,316 – 44,858) 26,719 (24,719 – 28,200) 
70-79 43,260 (38,903 – 46,469) 27,356 (24,702 – 29,402) 

























egion. Figure 6 shows important variations in regional complete- 
ess rates: Amazonas and Loreto (in Amazonia), and Pasco and Ca- 
amarca (in the Andes) show estimated completion at below 50%, 
hile Ica (coast) and Madre De Dios (Peru’s least populated region 
n Amazonia) appear to have complete registration (Appendix 1). 
Figure 7 shows observed and predicted values for registered ex- 
ess death rates by region for the age group over 80. Arequipa, 
adre De Dios, Moquegua are the regions with highest peaks. 
hese values show both seasonality and growth. This, along with 
he high number of statistically significant β1 parameters across 
egressions, indicates the model fits the data. As such, the vari- 
ble COVID-19 correctly identifies a significant change in mortality 
atterns across time. See Appendix 1 for statistics, goodness-of-fit 
nalysis and predictions for absolute deaths for all models. 
Table 1 summarises our estimates of excess mortality. Regis- 
ered excess mortality is estimated to be 108,943 (95% CI 96,507 - 
18,261), of which 37,725 are reported as COVID-19 deaths. Unreg- 
stered excess mortality is estimated to be 62,933 deaths (95% CI 
5,940 - 68,005), making up 58 • 9% (95% CI 46% - 79 • 4%) of our es-
imate of total registered and unregistered deaths. This third term 
dds 1,222 deaths corresponding to cases when reported COVID-19 
eaths exceed our estimate of adjusted registered excess mortal- 
ty. Combining all these terms, our estimate of total excess deaths 7 uring 2020 is 173,099 (95% CI 153,669 - 187,488) and our esti- 
ate of total deaths for 2020 is 334,043 (95% CI 300,147 - 367,743). 
his is 73 • 8% (95% CI 56 • 2% - 91 • 3%) more than the number of
eaths projected by INEI for 2020 (192,215) [46] , and 14 • 3% (95%
I 13 • 5 - 14 • 5) higher than estimations based on CRVS data in
019. See Appendix 1 for results and comparison with robustness 
nalysis. 
Table 2 shows estimates by region. Lima, which includes the 
apital, accounts for 87,781 (95% CI 82,294 – 92,504) total excess 
eaths, and Apurimac and Huancavelica show the lowest num- 
ers. Coastal regions have the highest values of unregistered ex- 
ess deaths, with Lima accounting for 36,856 additional deaths, 
ollowed by Piura (7,928) and Lambayeque (3,540). The highest 
nder-reported COVID-19 mortality occurs in the Andean regions 
f Ayacucho (192) and Apurimac (150), along with Ucayali, in Ama- 
onia (117). 
Table 3 presents excess mortality estimates by age group. Ex- 
ess deaths among people aged 60 years and over account for 
4 • 1% of total excess mortality. There was negative registered ex- 
ess mortality for the youngest age groups. 
Figure 8 shows all-cause age-standardised death rates. Callao, 
iura, and Lima have the highest rates, ranging from 10 • 3 to 13 • 9
CI 95% ranging from 10 • 1 to 13 • 9). Lambayeque, Cusco, and Ama-
onas show the lowest rates ranging from 4 • 44 to 7 • 98 (CI 95%
anging from 4 • 33 to 8 • 26). Figure 8 also shows differences in
eaths per 1,0 0 0 compared to INEI’s projections for 2020. There 
s excess mortality in all regions but Amazonas and Cusco. 
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Figure 7. Predicted registered excess death rates by 10 0 0 people by Region for age group over 80 - Peru. 
Figure 8. Estimated age-standardised mortality rates and differences with INEI projections. 
8 

























































































































Most published studies of excess COVID-19 mortality fall into 
wo categories. Some provide estimates for countries where mor- 
ality data are relatively complete and reliable [47–50] . As such, 
hey do not apply specific methods to address data gaps. To 
ur knowledge, previous studies of excess COVID-19 mortality for 
ountries with less complete data have not taken unregistered 
eaths into account [51–56] . 
Our method generates an estimate of all-cause excess mortal- 
ty of 173,099 (95% CI 153,669 - 187,488). If true, this is the high-
st per capita rate of excess mortality yet reported for any coun- 
ry during the pandemic. Available research indicates that this high 
eath rate resulted from a combination of causes, including a weak 
nd under-resourced health system, national and local policy fail- 
res and a wider context of poverty, inequality and precarious em- 
loyment [27-28] . 
Our estimate of all-cause excess mortality is 93% (95% CI 71% 
 109%) higher than official reports of total COVID-19 deaths for 
he same period [30] . This is a much larger differential than those 
eported by studies in high-income countries, where death regis- 
ration coverage is more complete. For example, separate studies 
f the US report differentials of 28% and 33%, respectively [ 11 , 12 ].
owever, under-registration of deaths does not fully account for 
his differential: our estimate of registered all-cause excess mor- 
ality was still 21% (95% CI 7% - 32%) higher than official figures. 
There are a number of other national estimates of excess mor- 
ality for Peru during the pandemic, based on different methodolo- 
ies. Quevedo et al compare registered deaths between April and 
une of 2020 to corresponding periods for 2017-19, but do not take 
on-registered deaths or improvements in data registration into 
ccount [56] . This produces an estimate of 36,322 excess deaths. 
pplying our approach to the same time period gives an estimate 
f 34,155 (CI 95% 30,257 - 37,178) registered excess deaths, increas- 
ng to 63,598 (CI 95% 52,703 - 67,213) when non-registered deaths 
re included. 
A separate study applies similar methods to Quevedo et al 
o compare 1 January to 12 July 2020 to corresponding periods 
n 2017-19 [57] . This produces an estimate of 46,863 excess re- 
orted deaths, compared to 41,440 registered excess deaths (CI 95% 
6,449 - 45,300), increasing to 72,692 (CI 95% 65,104 – 77,163) ap- 
lying our approach to the same period. This second study includes 
,0 0 0 excess deaths that occurred before March 2020, and which 
annot therefore be attributed to the COVID-19 pandemic. A third 
tudy of Lima metropolitan region compares the number of non- 
iolent deaths between the 1 st 24 weeks of 2019 and 2020 and 
nds 20,093 excess deaths [58] . This is larger than our own es- 
imate of excess registered deaths in Lima over the same period: 
2,513 (CI 95% 11,493 – 13,408), but very close to our total esti- 
ate when unregistered deaths are also included, 21,738 (CI 95% 
6,892 - 21,738). Together, these studies demonstrate the value of 
he more comprehensive methods applied in our study. 
No other published study for Peru provides data disaggregated 
y age groups. Studies for other countries show excess mortal- 
ty tends to be higher among older people. A study of registered 
xcess mortality in six Brazilian cities reports that people aged 
0 and over accounted for 71 • 1% of the total [53] . An analysis of
uropean countries reports that 91% of excess COVID-19 deaths 
ccurred among people aged 65 or more [9] . Similarly, Despite 
aking up a relatively low share of Peru’s population (12 • 5% in 
020), we find people aged 60 or more accounted for 73 • 9% of 
stimated excess mortality. By contrast, negative excess mortality 
mong Peruvians aged under 10 probably reflected the impact of 
easures taken to restrict the spread of SARS-CoV-2: an effect re- 
orted in other countries [59] . These measures appear to have re- 
uced deaths from causes such as unintentional injuries, road acci- 9 ents and street violence, as well as the transmission of other air- 
orne viruses, including influenza and respiratory infections com- 
on among younger children. 
No other published study for Peru takes geographical variations 
n mortality registration into account, in order to produce robust 
stimates data disaggregated by sub-region. Our finding that un- 
egistered mortality tends to be higher in poorer regions is con- 
istent with studies of other LMICs [60] . This will lead to larger 
nder-estimations of mortality in poorer regions in studies based 
urely on registered deaths. We estimate that all-cause excess 
ortality ranged from 0 • 55 per 1,0 0 0 people in Apurimac to 8 • 27
n Lima . Our estimates of regional variations for excess mortality 
n Peru are in line with a separate study, which posits they may be 
n part attributable to the effect of altitude on COVID-19 case fa- 
ality [56] . Geographical variations in COVID-19 transmission may 
lso have contributed to regional patterns of mortality. Specific 
arts of the country, including the capital city Lima and Iquitos (in 
mazonia), have seen especially high rates of reported seropreva- 
ence of anti-SARS-CoV-2 antibodies [28,29] . However, this may in 
art be an artefact of geographical variations in COVID-19 testing 
ates. 
Our analysis is limited by data availability and robustness. We 
o not take account potential SINADEF registration growth during 
020. We do not include it due to lack of robust historical data 
hat allows for robust estimations to avoid possible confounding 
ith demographic changes and other potential unknown exoge- 
ous shocks. Lambayeque is an example of poor data reliability, 
hich poses difficulties to estimate both registered and unregis- 
ered excess mortality. 
We also make several assumptions to simplify our analysis. We 
ssume comparison between years is not invalidated by specific 
ime-bound mortality events, such as additional disease outbreaks 
r other external shocks. We found no evidence of such events for 
he period in question. Our estimates of registration completeness 
ssume no variation across age groups and assume a linear pro- 
ression in registration, which may not be the case. Additionally, 
ur estimates are based on provisional data, which remain incom- 
lete and may subsequently be revised. While most death certifi- 
ates are entered into the online database in real-time, those pro- 
uced manually take additional time to process and be included. 
lso, these delays vary across regions. We assume that the effect of 
hese delays is negligible, as we are limiting our analysis to deaths 
hat occurred up to the end of 2020. Although some of the authors 
iscussed the SINADEF and MoH data processes and characteristics 
ith Peruvian government officials and regional experts, this does 
ot constitute an independent validation of these data sources. Fi- 
ally, we present a conservative scenario, allowing for both nega- 
ive and positive excess mortality. 
There is an evident need for robust estimates of the direct and 
ndirect mortality effects of the COVID-19 pandemic. To date, much 
f the data for LMICs rely on officially registered deaths. Inaccu- 
ate attribution of cause of death can, to some degree, be resolved 
y generating excess mortality estimates based on comparisons of 
ll-cause mortality over time. However, because of the substantial 
nder-registration of deaths in many LMICs, it is also crucial to ad- 
ust excess estimates to include deaths that were not officially reg- 
stered. 
This paper develops and applies a method to obtain robust 
xcess mortality estimates for both registered and unregistered 
eaths. These estimates suggest that official data for Peru substan- 
ially under-represent the overall mortality impact of the first pan- 
emic wave, and that this gap is much greater than those reported 
or high-income countries. 
It is plausible that the degree of underestimation of excess mor- 
ality in other countries with low-quality mortality data will be 
omparable to Peru. The framework, tools, and analytical strategy 















































pplied in this paper may therefore be useful for generating sim- 
lar estimates for these countries [61] . In Colombia, for example, 
ata quality is similar to Peru’s and a recent reform of its CRVS 
ystem is likely to have boosted registration rates in recent years 
62] . There is an urgent need to extend this research, in order to 
ssess the true toll of the COVID-19 pandemic, both globally and 
specially in LMICs. 
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